PharmaTher, a Toronto-based biotechnology company focused on discovering and developing drugs using Ketamine, received an Orphan Drug Designation (ODD) for a ketamine-based medicine to treat a rare seizure condition.
Status Epilepticus is characterized by a seizure lasting more than five minutes or having more than one seizure in a five-minute period, according to HopkinsMedicine.org. While all seizures can be dangerous, these are considered extremely severe and can lead to permanent brain damage and even death.
